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once annually during the study period of 2000–2005, were >=30
years old, and did not have a diagnosis of pregnancy or cancer.
Hospitalization attributable to diabetes was deﬁned as admis-
sions due to diabetes, diabetic complications, or cardiovascular
diseases. Cox-proportional hazard model was developed to
determine signiﬁcant factors for hospitalizations after adjusting
for the study variables. Two-part model (First part: logistic
regression and second part: generalized linear model with log
link function) was utilized to estimate mean length of stay.
RESULTS: A total of 7952 patients with type 2 diabetes were
identiﬁed with mean age of 57.4. Approximately 5.4% of them
were hospitalized due to diabetes. Type 2 diabetes patients were
more likely to be admitted if they were older than 65 years
(relative risk (RR) = 1.36; 95% conﬁdence interval
(95%CI) = 1.09–1.71), took both insulin and oral antidiabetic
medications (RR = 4.31; 95% CI = 3.30–5.63) compared to
patients without diabetic treatment, or had frequent physician
ofﬁce visits (RR = 2.06; 95% CI = 1.53–2.76). Overall, patients
stayed at the hospital on average of 2.23  0.08 days. CON-
CLUSION: Type 2 diabetes patients who took both insulin and
oral antidiabetic medications due to poor glucose control were
more likely to be admitted to hospital. It is recommended that
aggressive early intervention for controlling blood glucose and
improving compliance with diabetes treatment may prevent hos-
pitalizations related with diabetes.
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OBJECTIVE: Physician pay-for-performance are gaining
momentum as an approach to improve health care quality in the
United States. The objective of this study was to show the ben-
eﬁcial effects of physician incentive programs for the treatment of
diabetic patients as well as the potential for cost saving.
METHODS: Administrative claims data from a large regional
health plan were used through the 2004–2005 time-frame. Dia-
betic patients age 18–75 with private health insurance coverage
were included in the analysis. Multivariate Poisson regression
was used to model the likelihood of diabetes-related hospitaliza-
tions between patients who were being treated by a physician
participating in the incentive program and those that were not.
Likewise, cost savings associated with diabetic patients treated
by physicians participating in the incentive program was also
computed. RESULTS: Over a two year period, patients in the
P4P program showed a lower combined predicted number of
hospitalizations (0.31) than that of patients not in a P4P program
(0.39). In addition, cost beneﬁt analysis using decision tree mod-
eling showed the costs of the P4P program was entirely covered
by the reduction in cost resulting from decreased hospitalization
rates. With the incentive program, the health plan saved approxi-
mately $24 per adult diabetic and a total cost savings of
$675,000. Sensitivity analysis shows that the higher quality of
care resulting from the incentive based programs directly beneﬁts
outcomes of diabetes patients with an added beneﬁt of reducing
program cost. CONCLUSION: The cost savings associated with
physician pay-for-performance programs depend highly on the
effectiveness of the program to improve delivery of quality care.
Physician incentive programs have the potential to improve
patient outcomes as well as lead to economic beneﬁts for payers.
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OBJECTIVE: To develop a model to predict the probability of
diabetes patients having inpatient hospitalization in the follow-
ing year. METHODS: A retrospective cohort study was con-
ducted based on a population of 322 type II diabetes patients age
>=19 and enrolled in a Medicaid managed care plan from the
year 2003 to 2005. Models were developed by using medical/
pharmacy utilization data to predict the probability of having the
following events in the next year: (1) whether the patient had any
inpatient hospitalization, (2) whether the patient had any micro/
macro vascular inpatient hospitalization, (3) whether the patient
had any metabolic related inpatient hospitalization and (4)
whether the patient had any infectious inpatient hospitalization.
Main predictors of interests are diabetes compliance and the use
of statin. Covariates include diabetes treatment pattern, age, sex,
co-morbidities among other variables. Logistic model is used to
conduct the analysis. RESULTS: The study population was 74%
female with an average age of 49.2 (S.D = 8.4). Non-adherence
of diabetes drug (odds ratio = 1.57, 95% CI: 1.09–2.24), use of
statin (odds ratio = 0.58, 95% CI: 0.39–0.85), and previous
inpatient history (odds ratio = 3.50, 95% CI: 2.42–5.07) were
signiﬁcant in predicting any inpatient hospitalization. Non-
adherence of diabetes drugs was not a signiﬁcant predictor for
micro/macro vascular events (odds ratio = 0.74, 95% CI: 0.33–
1.67), but it was associated with signiﬁcantly increased prob-
abilities of having metabolic events (odds ratio = 1.58, 95% CI:
1.03–2.43) and infectious events (odds ratio = 2.70, 95% CI:
1.10–6.66). The use of statin was signiﬁcant only for predicting
metabolic events (odds ratio = 0.49, 95% CI: 0.32–0.77). It was
not signiﬁcant for predicting vascular events (odds ratio = 0.98,
95% CI: 0.45–2.15) and infectious events (odds ratio = 1.40,
95% CI: 0.49–3.72). CONCLUSION: The modeling results
show that improving compliance of diabetes drug and encourag-
ing the use of statin could be associated with reducing inpatient
hospitalizations in a short period of time.
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OBJECTIVE: To assess the budgetary impact of adding the ﬁxed-
dose pioglitazone plus glimepiride to a managed care formulary
plan over a three-year period (2006–2008). METHODS: This
model is an Excel-based spreadsheet which assumes a hypotheti-
cal scenario wherein a plan comprising one million covered lives
assesses the ﬁnancial impact of pioglitazone plus glimepiride to
formulary. The prevalence of type 2 diabetes is assumed to be
4.64% or approximately 46,400 members. Existing oral anti-
diabetic (OAD) agents on the formulary include TZDs (pioglita-
zone, rosiglitazone, TZD combinations with metformin, &
rosiglitazone plus glimepiride), sulfonylureas (glipizide, gly-
buride, glimeperide), metformin, & a DPP4 inhibitor (sitaglip-
tin). Costs for these agents were based on WAC (2006). Market
shares were based on internal market research and IMS data.
Metrics of budgetary impact are reported in terms of annual
treatment costs & per member per month (PMPM) costs. These
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metrics were adjusted for patient compliance with OADs as
reported in the literature. These metrics are reported as adjusted
and unadjusted estimates for patient compliance over a three-
year time frame. RESULTS: In this scenario, market share for
pioglitazone plus glimepiride was assumed to increase from
0.04% (2006) to 0.36% (2007) to 0.50% (2008). Projected
annual treatment costs adjusted for compliance ranged from
$22,240 (2006) to $200,164 (2007) to $278,006 (2008). Unad-
justed estimates range from $35,295 (2006) to $317,652 (2007)
to $441,183 (2008). Projected PMPM costs adjusted for compli-
ance ranged from $0.002 (2006) to $0.017 (2007) to $0.023
(2008). Unadjusted PMPM estimates range from $0.003 (2006)
to $0.026 (2007) to $0.037 (2008). CONCLUSION: The budget
impact of adding pioglitazone plus glimepiride on formulary was
minimal over a three-year time frame in both scenarios. This is
driven by anticipated market projections estimating the utiliza-
tion of pioglitazone plus metformin among the class of OAD
agents.
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OBJECTIVE: There is a practically stable 5.3 % prevalence of
diabetes mellitus (DM) in Slovakia. The treatment ratio was as
follows: 47.6 % patients are on diet, 30.8 % on PAD and 21.6 %
on insulin. The main objective of this study was to determine if
the intensiﬁed insulin therapy with insulin pen is cost-effective
compared to conventional therapy. METHODS: Direct medical
an non direct costs were evaluated in retrospective randomized
study in patients with DM type 2. A group of 48 patients on
intensiﬁed insulin therapy (IIT) was compared with a group of 28
patients treated with conventional therapy (CT). RESULTS: The
average duration of DM was 113.51 months in IIT group and
147.67 months in CT group. The signiﬁcant difference
(p < 0.05,s) was observed in age (53.19 in IIT vs 55.11 in CT)
and in serum cholesterol (6.14 in ITT vs 6.65 in CT). The
hospital costs were higher in IIT: €568 vs. €511 in CT. The
laboratory costs were lower in IIT: €133 vs. €167 in CT. IIT had
higher costs for reimbursed drugs, glucometers and insulin pens
by Health Insurance Companies: €1065 vs. €1024 in CT. No
statistical difference was recorded in co-payments: €99 in IIT vs.
€100 in CT. Indirect patients costs based on time loss were €185
in IIT vs. €227 in CT. The total costs per patient per year were
€1972 in IIT vs. €1964 in CT. CONCLUSION: The treatment of
DM type 2 with insulin pen NovoPen® 3 is clinically and eco-
nomically effective in comparison to the treatment with syringe.
The estimated costs of LYS are €4759 in men and €6519 in
women per patient with DM in Slovakia.
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OBJECTIVE: To assess the impact of Apidra®, a new rapid-
acting insulin analog used in type 1 and 2 diabetes, on the health
care system in Poland. METHODS: Budget impact analysis has
been programmed using Microsoft Excel® 2003. Five-year
population-based model assumes that Apidra® will gain market
shares from rapid- and short acting insulins in proportion to their
original market shares distribution. Limit and reimbursement
rate of Apidra® was set equal to that of other rapid/short acting
insulins. In addition to the cost of insulins, the cost of blood
glucose monitoring strips was included in the total annual costs.
The perspective of: 1) public payer, 2) public payer + patient; was
considered separately. A range of compliance levels were also
taken into account. Sensitivity analysis (including the analysis of
extreme scenarios—most pessimistic and optimistic) was per-
formed to account for uncertainty in input parameters.
RESULTS: Financing Apidra® from public means will have no
consequences for a public payer, which results from equal limits
for all rapid- and short acting insulins. From the perspective of
both payers for health care services (NHF and patient), incre-
mental costs associated with introducing Apidra® to the market
increase from 642–1 018 PLN (0.0001–0.0002%) in year one to
20 307–32 226 PLN (0.0044–0.005%) in the 5th year post-
launch, depending on the drug compliance level assumed (230 or
365 days/year). Results were most sensitive to the change of
Apidra(r) price. CONCLUSION: Results of the analysis indicate
that decision to ﬁnance Apidra® from public means in Poland
would have no consequences for a public payer, and the impact
from the perspective of both payers (public payer and patient) is
not likely to be signiﬁcant.
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OBJECTIVE: Somatropin is human growth hormone (GH) pro-
duced by recombinant DNA technology. Several somatropin
products with unique delivery devices are available. When
administering the last dose from a device, patients may have an
insufﬁcient amount of GH remaining for a full dose. Based on a
survey of parents/patients using pen devices conducted at the
2007 MAGIC Foundation Convention, 63% of respondents
reported that they were likely to discard this remaining amount
left in the cartridge (i.e., waste). easypod, an electronic GH
delivery device for somatropin (rDNA origin) for injection (EMD
Serono, Inc.), contains a dose spread feature designed to mini-
mize waste. A model was developed to estimate potential GH
waste per patient with pen devices and the easypod device and
quantify the potential annual economic impact. METHODS:
Base case model utilizes a daily dose (2 mg) reﬂective of the
national mean for all GH pen devices (Wolters Kluwer, 2007). A
10% mechanical loss is applied uniformly across all devices
based on the reported mechanical loss in the prescribing infor-
mation for somatropin (rDNA origin) for injection (EMD
Serono, Inc.). Model assumes that the easypod dose spread func-
tion (10%;25%; or50%) is activated by the clinician (base
case utilizes25%). This function minimizes waste by automati-
cally adjusting the daily dose (+/-) to optimize the cartridge
content; the cumulative average of injected doses is equal to the
prescribed daily dose. Annual cost of GH waste per patient for
each device is reported (wholesale acquisition cost, Medispan,
2007). RESULTS: Expected annual cost of GH waste per patient
was lowest for easypod ($112). Results for pen devices ranged
from $794 to $3363 (using largest cartridge size for each
product). Results ﬂuctuate depending on daily dose, cartridge
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